. . . still looking to dump my arna shares so I can buy more OREX . . .
. . . put all your assets into one stock? . . . nothing more foolish than that, sc . . . that's probably why so many areniacs live in fear and are pathologically focused on OREX's possible success . . .
. . . actually, anitdua, that may already be a fait accompli: from the company's 12/11 news release . . . "By agreement with the FDA, the independent Data Monitoring Committee's summary report of the Light Study interim analysis formed the basis of the resubmission of the NDA. The interim analysis clinical study report (CSR) will be supplied to the FDA within 60 days of the NDA resubmission. The review period for the resubmission is expected to be six months." . . .
. . . just asking a question . . . why so scared? . . . if you're not . . . then don't bother to respond . . .
. . . I'm interested in an answer, really . . . I've never understood the pathological posting on this board and the OREX board by arna investors . . . what's your point? . . . to assuage your worries? . . .
. . . areniacs . . . still scared to death of OREX . . . do you people have to sleep with night lights? . . . just curious . . .
. . . why are you people so worried about a competitor you are certain will never make it to market? . . . what gives? . . . and I ask that still owning both of them . . .
. . . not yet, sc . . . but wait until next year and you may be reading one for the U.S. and one for Europe as well . . .
. . . well, q1, people do die . . . but not always due to the side effects of a drug . . . but since your decimating belviq's scientific facts, can you explain why MF's Eric Ho wrote on 11/26 ". . . Belviq's label still carries warnings against rare but potentially fatal heart valve and neurological side effects" . . . is that really true? . . .
. . . so which facts about the science of belviq have you recently decimated? . . . you've got my interest now . . .
. . . areniacs are always lookin' over their shoulders . . . shakin' in their boots . . . too funny . . .
. . . why are you so concerned about Contrave, if it's such a nonstarter? . . . personally, I'm more worried about my shares of ARNA . . .
. . . equity markets are always forward looking, di . . . OREX's market cap and high institutional ownership simply reflect WS's confidence that the company will come to market with a superior product in 2014 to compete against ARNA and will also be first to gain European approval . . . at that point, I would also expect OREX to have gained market cap parity with ARNA . . .